Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 7, Issue 18
September 26 2023
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Haplo ever after: haplo PTCy for children
Julie-An Talano,Larisa Broglie
View Articletitled, Haplo ever after: haplo PTCy for children
Histidine-rich glycoprotein: antithrombosis without bleeding
Alvin H. Schmaier
View Articletitled, Histidine-rich glycoprotein: antithrombosis without bleeding
Remission after rituximab for HHV8+ MCD: what next?
Clinical Trials & Observations
Ramya Ramaswami,Thomas S. Uldrick
View Articletitled, Remission after rituximab for HHV8<sup>+</sup> MCD: what next?

REVIEW ARTICLES

The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
Itziar Salaverria,Oliver Weigert,Leticia Quintanilla-Martinez
View Articletitled, The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas
It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma
Ruth Choa,Cristina Panaroni,Roma Bhatia,Noopur Raje
View Articletitled, It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma

SYSTEMATIC REVIEW

Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Tanaporn Meejun,Karan Srisurapanont,Kasama Manothummetha,Achitpol Thongkam,Nuthchaya Mejun,Nipat Chuleerarux,Anawin Sanguankeo,Kasidis Phongkhun,Surachai Leksuwankun,Jaedvara Thanakitcharu,Bhoowit Lerttiendamrong,Nattapong Langsiri,Pattama Torvorapanit,Navaporn Worasilchai,Rongpong Plongla,Nattiya Hirankarn,Saman Nematollahi,Nitipong Permpalung,Chatphatai Moonla,Olivia S. Kates
View Articletitled, Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
Clinical Trials & Observations
Juan Rangel-Patiño,Yu Ling Lee-Tsai,Victor Itaí Urbalejo-Ceniceros,Maria Elena Monserrat Luna-Perez,Karla Adriana Espinosa-Bautista,Lauro Fabian Amador,Álvaro Cabrera-García,Carolina Balderas-Delgado,Sergio I Inclan-Alarcon,Yvette Neme-Yunes,Jose Manuel Sanchez-Albarrán,Elia Ixel Apodaca,Luis Meillon-García,Wendy Stock,Roberta Demichelis-Gómez
View Articletitled, A modified CALGB 10403 in adolescents and young adults with acute lymphoblastic leukemia in Central America
Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
Clinical Trials & Observations
Scott R. Solomon,Melhem Solh,Lawrence E. Morris, Jr.,H. Kent Holland,Lizamarie Bachier-Rodriguez,Xu Zhang,Caitlin Guzowski,Katelin C Jackson,Stacey Brown,Asad Bashey
View Articletitled, Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
Supplemental data
Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Clinical Trials & Observations
Shai Shimony,Yael Flamand,Yannis K. Valtis,Andrew E. Place,Lewis B. Silverman,Lynda M. Vrooman,Andrew M. Brunner,Stephen E. Sallan,Richard M. Stone,Martha Wadleigh,Donna S. Neuberg,Daniel J. DeAngelo,Marlise R. Luskin
View Articletitled, Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials
Supplemental data
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Clinical Trials & Observations
Dmitry Evseev,Daria Osipova,Irina Kalinina,Elena Raykina,Anna Ignatova,Evelina Lyudovskikh,Dina Baidildina,Alexander Popov,Vladimir Zhogov,Alexandra Semchenkova,Eugeny Litvin,Natalia Kotskaya,Ekaterina Cherniak,Kirill Voronin,Eugeny Burtsev,Gleb Bronin,Irina Vlasova,Bazarma Purbueva,Olesya Fink,Ekaterina Pristanskova,Irina Dzhukaeva,Elena Erega,Galina Novichkova,Alexey Maschan,Michael Maschan
View Articletitled, Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
Supplemental data
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Clinical Trials & Observations
Pier Luigi Zinzani,Armando Santoro,Giuseppe Gritti,Pauline Brice,Paul M. Barr,John Kuruvilla,David Cunningham,Justin Kline,Nathalie A. Johnson,Neha Mehta-Shah,Julie Lisano,Rachael Wen,Alev Akyol,Alison J. Moskowitz
View Articletitled, Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
Supplemental data
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Clinical Trials & Observations
Carol Moreno,Isabelle G. Solman,Constantine S. Tam,Andrew Grigg,Lydia Scarfò,Thomas J. Kipps,Srimathi Srinivasan,Raghuveer Singh Mali,Cathy Zhou,James P. Dean,Edith Szafer-Glusman,Michael Choi
View Articletitled, Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Supplemental data
Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Clinical Trials & Observations
Vikas Gupta,John Mascarenhas,Marina Kremyanskaya,Raajit K. Rampal,Moshe Talpaz,Jean-Jacques Kiladjian,Alessandro M. Vannucchi,Srdan Verstovsek,Gozde Colak,Debarshi Dey,Claire Harrison
View Articletitled, Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
Supplemental data
Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
Clinical Trials & Observations
John Moore,Nada Hamad,David Gottlieb,Ashish Bajel,David Ritchie,David Yeung,Matthew Greenwood,Duncan Purtill,Steven Tran,Annie Solterbeck,Donna Aarons,John Kwan
View Articletitled, Early cessation of calcineurin inhibitors is feasible post–haploidentical blood stem cell transplant: the ANZHIT 1 study
Supplemental data
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Clinical Trials & Observations
Michael Scordo,Jessica R. Flynn,Mithat Gonen,Sean M. Devlin,Allison Parascondola,Ana Alarcon Tomas,Roni Shouval,Jamie Brower,David L. Porter,Stephen J. Schuster,Veronika Bachanova,Joseph Maakaron,Richard T. Maziarz,Andy I. Chen,Loretta J. Nastoupil,Joseph P. McGuirk,Olalekan O. Oluwole,Andrew Ip,Lori A. Leslie,Michael R. Bishop,Peter A. Riedell,Miguel-Angel Perales
View Articletitled, Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Supplemental data
Higher rate of progression in HIV– than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease
Clinical Trials & Observations
Camille Rasmussen,Laurence Gérard,Jehane Fadlallah,Emilie Corvilain,Lionel Galicier,Véronique Meignin,Eric Oksenhendler,David Boutboul
View Articletitled, Higher rate of progression in HIV<sup>–</sup> than in HIV<sup>+</sup> patients after rituximab for HHV8<sup>+</sup> multicentric Castleman disease
Supplemental data
Remission after rituximab for HHV8+ MCD: what next?
Clinical Trials & Observations
Ramya Ramaswami,Thomas S. Uldrick
View Articletitled, Remission after rituximab for HHV8<sup>+</sup> MCD: what next?

HEMATOPOIESIS AND STEM CELLS

Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation
Roni Tamari,Michael Scordo,Binni M. Kunvarjee,Anthony Proli,Andrew Lin,Jessica Flynn,Christina Cho,Sean Devlin,Elizabeth Klein,Farid Boulad,Maria I. Cancio,Kevin J. Curran,Ann A. Jakubowski,Nancy A. Kernan,Andrew L. Kung,Richard J. O’Reilly,Esperanza B. Papadopoulos,Susan Prockop,Andromachi Scaradavou,Brian C. Shaffer,Gunjan Shah,Barbara Spitzer,Boglarka Gyurkocza,Sergio A. Giralt,Miguel-Angel Perales,Jaap Jan Boelens
View Articletitled, Association between busulfan exposure and survival in patients undergoing a CD34<sup>+</sup> selected stem cell transplantation
Supplemental data
Single-cell multiomics of human fetal hematopoiesis define a developmental-specific population and a fetal signature
Mikael N. E. Sommarin,Rasmus Olofzon,Sara Palo,Parashar Dhapola,Shamit Soneji,Göran Karlsson,Charlotta Böiers
View Articletitled, Single-cell multiomics of human fetal hematopoiesis define a developmental-specific population and a fetal signature
Supplemental data
Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice
Koki Nagai,Tetsuya Niihori,Akihiko Muto,Yoshikazu Hayashi,Taiki Abe,Kazuhiko Igarashi,Yoko Aoki
View Articletitled, <em>Mecom</em> mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice
Supplemental data
ETV6 represses inflammatory response genes and regulates HSPC function during stress hematopoiesis in mice
Mackenzie Bloom,Ninad Oak,Rebekah Baskin-Doerfler,Ruopeng Feng,Ilaria Iacobucci,Pradyumna Baviskar,Xujie Zhao,Alexa N. Stroh,Chunliang Li,Patrick Ozark,Heather S. Tillman,Yichao Li,Katherine C. Verbist,Sabrin Albeituni,Danny C. Scott,Moeko T. King,Shannon L. McKinney-Freeman,Mitchell J. Weiss,Jun J. Yang,Kim E. Nichols
View Articletitled, ETV6 represses inflammatory response genes and regulates HSPC function during stress hematopoiesis in mice
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Low leukemia DR score predicts poor response to CAR T-cells but can be raised by neoadjuvant low-dose total tumor irradiation, which improves CAR T-cell response in mice.

Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
Alexander B. Kim,Ssu-Yu Chou,Solomon Kang,Eric Kwon,Matthew Inkman,Jeff Szymanski,Neal Andruska,Cian Colgan,Jin Zhang,Joanna C. Yang,Nathan Singh,Carl J. DeSelm
View Articletitled, Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation
Supplemental data
Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
Jessica S. Little,Megha Tandon,Joseph Seungpyo Hong,Omar Nadeem,Adam S. Sperling,Noopur Raje,Nikhil Munshi,Matthew Frigault,Sara Barmettler,Sarah P. Hammond
View Articletitled, Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
Clinical Trials & Observations
Sara K. Silbert,Sanna Madan,Elizabeth M. Holland,Seth M. Steinberg,Lauren Little,Toni Foley,Monica Epstein,Angela Sarkisian,Daniel W. Lee,Ekaterina Nikitina,Showri Kakumanu,Eytan Ruppin,Haneen Shalabi,Bonnie Yates,Nirali N. Shah
View Articletitled, A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials
Supplemental data

LYMPHOID NEOPLASIA

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
Anna Nikkarinen,Lavanya Lokhande,Rose-Marie Amini,Mats Jerkeman,Anna Porwit,Daniel Molin,Gunilla Enblad,Arne Kolstad,Riikka Räty,Martin Hutchings,Caroline E. Weibull,Peter Hollander,Sara Ek,Ingrid Glimelius
View Articletitled, Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
Supplemental data
Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
Thomas A. Ollila,Rashida Taher,Prashanth Moku,Adam J. Olszewski
View Articletitled, Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
David A. Russler-Germain,Kilannin Krysiak,Cody Ramirez,Matthew Mosior,Marcus P. Watkins,Felicia Gomez,Zachary L. Skidmore,Lee Trani,Feng Gao,Susan Geyer,Amanda F. Cashen,Neha Mehta-Shah,Brad S. Kahl,Nancy L. Bartlett,Juan P. Alderuccio,Izidore S. Lossos,Sarah L. Ondrejka,Eric D. Hsi,Peter Martin,John P. Leonard,Malachi Griffith,Obi L. Griffith,Todd A. Fehniger
View Articletitled, Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
Supplemental data
Sézary syndrome originates from heavily mutated hematopoietic progenitors
Carly M. Harro,Kimberly B. Sprenger,Ricardo A. Chaurio,John J. Powers,Patrick Innamarato,Carmen M. Anadon,Yumeng Zhang,Subir Biswas,Gunjan Mandal,Jessica A. Mine,Carla Cortina,Mate Z. Nagy,Alexandra L. Martin,Katelyn F. Handley,Gustavo J. Borjas,Pei-Ling Chen,Javier Pinilla-Ibarz,Lubomir Sokol,Xiaoqing Yu,Jose R. Conejo-Garcia
View Articletitled, Sézary syndrome originates from heavily mutated hematopoietic progenitors
Supplemental data

MYELOID NEOPLASIA

In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
Bin E. Li,Grace Y. Li,Wenqing Cai,Qian Zhu,Davide Seruggia,Yuko Fujiwara,Christopher R. Vakoc,Stuart H. Orkin
View Articletitled, In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice
Supplemental data
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
Maria Rodriguez-Zabala,Ramprasad Ramakrishnan,Katrin Reinbach,Somadri Ghosh,Leal Oburoglu,Antoni Falqués-Costa,Kishan Bellamkonda,Mats Ehinger,Pablo Peña-Martínez,Noelia Puente-Moncada,Henrik Lilljebjörn,Jörg Cammenga,Cornelis Jan Pronk,Vladimir Lazarevic,Thoas Fioretos,Anna K. Hagström-Andersson,Niels-Bjarne Woods,Marcus Järås
View Articletitled, Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
Supplemental data
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
Sumanth Mosale Seetharam,Yi Liu,Jason Wu,Lenn Fechter,Kanagavel Murugesan,Holden Maecker,Jason Gotlib,James Zehnder,Ramasamy Paulmurugan,Anandi Krishnan
View Articletitled, Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens
Supplemental data
Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
Anna Stengel,Manja Meggendorfer,Wencke Walter,Constance Baer,Niroshan Nadarajah,Stephan Hutter,Wolfgang Kern,Torsten Haferlach,Claudia Haferlach
View Articletitled, Interplay of <em>TP53</em> allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

RED CELLS, IRON, AND ERYTHROPOIESIS

Plasmodium falciparum infection of human erythroblasts induces transcriptional changes associated with dyserythropoiesis
Tamar P. Feldman,Yana Ryan,Elizabeth S. Egan
View Articletitled, <em>Plasmodium falciparum</em> infection of human erythroblasts induces transcriptional changes associated with dyserythropoiesis
Supplemental data

THROMBOSIS AND HEMOSTASIS

Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
Joey Ward,Ngoc-Quynh Le,Suryakant Suryakant,Jennifer A. Brody,Philippe Amouyel,Anne Boland,Rosemary Bown,Breda Cullen,Stéphanie Debette,Jean-François Deleuze,Joseph Emmerich,Nicholas Graham,Marine Germain,Jana J. Anderson,Jill P. Pell,Donald M. Lyall,Laura M. Lyall,Daniel J. Smith,Kerri L. Wiggins,José Manuel Soria,Juan Carlos Souto,Pierre-Emmanuel Morange,Nicholas L. Smith,David-Alexandre Trégouët,Maria Sabater-Lleal,Rona J. Strawbridge
View Articletitled, Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
Supplemental data
Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia
Yohei Hisada,Tomohiro Kawano,Sierra J. Archibald,John S. Welch,Brandi N. Reeves,Nigel Mackman
View Articletitled, Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia
Supplemental data
Histidine-rich glycoprotein attenuates catheter thrombosis
Rida A. Malik,Peng Liao,Ji Zhou,Rawaa Hussain,James C. Fredenburgh,Lisa Hettrick,Alexey S. Revenko,Jeffrey I. Weitz
View Articletitled, Histidine-rich glycoprotein attenuates catheter thrombosis
Supplemental data
Histidine-rich glycoprotein: antithrombosis without bleeding
Alvin H. Schmaier
View Articletitled, Histidine-rich glycoprotein: antithrombosis without bleeding

TRANSPLANTATION

Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
Xin Zhang,Jiabao He,Ke Zhao,Shiqi Liu,Li Xuan,Shan Chen,Rongtao Xue,Ren Lin,Jun Xu,Yan Zhang,Andy Peng Xiang,Hua Jin,Qifa Liu
View Articletitled, Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice
Supplemental data
EASIX-1year and late mortality after allogeneic stem cell transplantation
Clinical Trials & Observations
Lambros Kordelas,Tobias Terzer,Ted Gooley,Chris Davis,Brenda M. Sandmaier,Mohamed Sorror,Olaf Penack,Nigel D. E. Schaeper,Igor W. Blau,Dietrich Beelen,Aleksandar Radujkovic,Peter Dreger,Thomas Luft
View Articletitled, EASIX-1year and late mortality after allogeneic stem cell transplantation
Supplemental data
Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
Clinical Trials & Observations
Maddalena Noviello,Francesca Lorentino,Elisabetta Xue,Sara Racca,Giulia Furnari,Veronica Valtolina,Edoardo Campodonico,Roee Dvir,Maria Teresa Lupo-Stanghellini,Fabio Giglio,Simona Piemontese,Daniela Clerici,Chiara Oltolini,Elena Tassi,Valeria Beretta,Francesca Farina,Daniele Mannina,Anna Ardemagni,Luca Vago,Massimo Bernardi,Consuelo Corti,Jacopo Peccatori,Massimo Clementi,Fabio Ciceri,Chiara Bonini,Raffaella Greco
View Articletitled, Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
Supplemental data
Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
Clinical Trials & Observations
Juan C. Fierro-Pineda,Hua-Ling Tsai,Amanda Blackford,Andrew Cluster,Emi Caywood,Jignesh Dalal,Jeffrey Davis,Maarten Egeler,Jeffrey Huo,Michelle Hudspeth,Amy Keating,Susan S. Kelly,Joerg Krueger,Dean Lee,Leslie Lehmann,Lisa Madden,Benjamin Oshrine,Michael A. Pulsipher,Terry Fry,Heather J. Symons
View Articletitled, Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias
Haplo ever after: haplo PTCy for children
Julie-An Talano,Larisa Broglie
View Articletitled, Haplo ever after: haplo PTCy for children

RESEARCH LETTERS

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Clinical Trials & Observations
Zachary D. Crees,Michael P. Rettig,Asad Bashey,Steven M. Devine,Samantha Jaglowski,Fei Wan,Amy Zhou,Melinda Harding,Abi Vainstein-Haras,Ella Sorani,Irit Gliko-Kabir,Brenda J. Grossman,Peter Westervelt,John F. DiPersio,Geoffrey L. Uy
View Articletitled, Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Supplemental data
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Clinical Trials & Observations
Francis Ayuk,Nico Gagelmann,Bastian von Tresckow,Gerald Wulf,Kai Rejeski,Matthias Stelljes,Olaf Penack,Claudia D. Baldus,Nicolaus Kröger,Wolfgang Bethge,Peter Dreger
View Articletitled, Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Supplemental data
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
Clinical Trials & Observations
Rahul Lakhotia,Kieron Dunleavy,Jeremy S. Abramson,Brian K. Link,Bayard L. Powell,Christopher Melani,Andrea N. Lucas,Seth M. Steinberg,Jonathan W. Friedberg,Brad S. Kahl,Richard F. Little,Nancy L. Bartlett,Ariela Noy,Wyndham H. Wilson,Mark Roschewski
View Articletitled, Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
Clinical Trials & Observations
Shai Shimony,Geoffrey Fell,Evan C. Chen,Harrison K. Tsai,Martha Wadleigh,Eric S. Winer,Jacqueline S. Garcia,Marlise R. Luskin,Maximilian Stahl,Donna S. Neuberg,Daniel J. DeAngelo,R. Coleman Lindsley,Richard M. Stone
View Articletitled, <em>FLT3-ITD</em> does not predict inferior prognosis in acute myeloid leukemia patients aged ≥60 years
Supplemental data
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
Clinical Trials & Observations
Faheem Farooq,Justin S. Brandt,Elyce Cardonick,Evgeniya Polushkina,Julie Vose,Sairah Ahmed,Praveen Ramakrishnan Geethakumari,Adam J. Olszewski,Hesham Yasin,Umar Farooq,Nada Hamad,Yong Lin,Charlotte Maggen,Robert Fruscio,Mina Mhallem Gziri,Karina Dahl Steffensen,Frédéric Amant,Andrew M. Evens
View Articletitled, An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
Ariel Kleman,Arun Singavi,Lauren Pommert,Angela J. Mathison,Parameswaran Hari,Binod Dhakal,Meera Mohan,Siegfried Janz,Jennifer M. Knight,Mithun V. Shah,Carolina Schinke,Robert Burns,George Francis Steinhardt,Sridhar Rao,Karen Carlson
View Articletitled, A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
Supplemental data
Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
Matthew R. Schuelke,Hamid Bassiri,Edward M. Behrens,Scott Canna,Colleen Croy,Amanda DiNofia,Kandace Gollomp,Stephan Grupp,Michele Lambert,Arathi Lambrix,Shannon L. Maude,Regina Myers,Haley Newman,Whitney Petrosa,Alix Seif,Kathleen E. Sullivan,David T. Teachey,Caroline Diorio
View Articletitled, Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
Supplemental data

COMMENTARIES

Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?
Suely M. Rezende,Kenneth A. Bauer,Neil A. Zakai
View Articletitled, Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?
Addressing fertility in adolescent boys with sickle cell disease: emerging clinical and ethical dilemmas
Leena Nahata,Gwendolyn P. Quinn,John J. Strouse,Susan E. Creary
View Articletitled, Addressing fertility in adolescent boys with sickle cell disease: emerging clinical and ethical dilemmas

ERRATA

Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022;6(17):5160-5164.
View Articletitled, Lisi V, Blanchard È, Vladovsky M, et al. Unified gene expression signature of novel <em>NPM1</em> exon 5 mutations in acute myeloid leukemia. <em>Blood Adv.</em> 2022;6(17):5160-5164.
Hertz L, Flormann D, Birnbaumer L, et al. Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept. Blood Adv. 2023;7(6):1033-1039.
View Articletitled, Hertz L, Flormann D, Birnbaumer L, et al. Evidence of in vivo exogen protein uptake by red blood cells: a putative therapeutic concept. <em>Blood Adv</em>. 2023;7(6):1033-1039.
  • Cover Image

    Cover Image

    issue cover

    Schematic overview of B-cell differentiation deregulation by the constitutive activation of IRF4 and/or NF-κB, which induces the oncogenic transcription program in large B-cell lymphoma-IRF4. See the article by Salaverria et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement

Nuclear Receptor Rev-erbα Role in Fine-Tuning Erythropoietin Gene Expression
Active infection at the time of CD34+ selected stem cell boost is associated with treatment failure and poor survival
Biological and Clinical Determinants Shaping Heterogeneity in Mantle Cell Lymphoma
Targeting metabolic dependencies in JAK2-V617F–driven MPNs
Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement